细胞共同生产胰岛素和葡萄糖在先天性超胰岛素症
Yuliya Krivova1, Alexandra Proshchina1, Dmitry Otlyga1
1Laboratory of Nervous System Development, Avtsyn Research Institute of Human Morphology of FSBSI "Petrovsky National Research Centre of Surgery", Tsurupi Street, 3, 117418 Moscow, Russia.
Life (Basel, Switzerland)
|January 28, 2026
概括
患有先天性高胰岛素症 (CHI) 的婴儿表现出胰腺小岛细胞表型的改变,包括增加双激素细胞和减少PDX1表达,可能会影响低血糖症下胰岛素的产生.
科学领域:
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
- 儿科代谢 儿科代谢
背景情况:
- 胰腺小岛细胞表型变化与糖尿病和胰岛素缺乏有关.
- 有限的数据存在于低血糖症的小岛细胞变化,特别是在先天性高胰岛素症 (CHI) 的婴儿中.
研究的目的:
- 调查先天性高胰岛素症 (CHI) 婴儿胰岛岛细胞表型的变化.
- 为了比较分散的CHI,焦点CHI和未受影响的胰腺组织中的小岛细胞表型.
主要方法:
- 分析了患有扩散性CHI (n=6) 和焦点性CHI (n=5) 的婴儿手术胰腺活检.
- 对胰岛素,葡萄糖素和PDX1 (一种关键的β细胞转录因子) 进行了双重免疫光染色.
- 在受影响的小岛 (扩散性CHI) 和焦点病变中的细胞表型与未受影响的小岛相比较.
主要成果:
- 在扩散性CHI中观察到更高比例的双激素胰岛素+/葡萄糖+细胞.
- 在扩散性CHI和焦点性CHI病变中发现缺乏PDX1的胰岛素+细胞的百分比增加.
- 这些发现表明,在CHI的低血糖条件下,β细胞的表型变化.
结论:
- 患有CHI的婴儿表现出改变的胰岛岛细胞表型,其特征是双激素细胞和PDX1-负细胞的增加.
- 这些表型变化可能会导致CHI中的胰岛素失调.
- 需要进一步的研究来确定小岛细胞可塑性在CHI病变发生过程中的作用.
相关概念视频
Hypoglycemia and Glucagon
961
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
961
Glucagon-like Receptor Agonists
902
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
902
Insulin Secretory Vesicles
6.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.8K
Insulin: The Receptor and Signaling Pathways
3.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.0K
Insulin Formulations: Types and Delivery
717
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
717
Insulin: Biosynthesis, Chemistry, and Preparation
1.3K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.3K


